Security key
20678X205
CONDUIT PHARMACEUTICALS INC. - Common Stock (CDT)
CUSIP: 20678X205
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 493,468
- Total 13F value
- $385,113
- Share change
- +491,211
- SEC-reported price per share
- $0.78
- Number of holders
- 31
- Value change
- +$383,312
- Number of buys
- 29
- Number of sells
- 1
- Shares outstanding
- 11,304,470
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
31
Top holders
10
CDT full security history
Ownership snapshot
Full 13F holder table
CDT Equity Inc. SEC filings
CDT Equity Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CDT - CONDUIT PHARMACEUTICALS INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sarborg Ltd
Disclosed value leader
Sarborg Ltd
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
3/4/5
13F
Lead comparable stake: 16%
13D/G row: Sarborg Ltd
Showing 1-6 of 15 holder rows.
Quick read
Sarborg Ltd leads the comparable SEC ownership view at 16%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sarborg Ltd's linked filing trail.
Comparable ownership
Top 5
Sarborg Ltd
16%
A.G.P. / ALLIANCE GLOBAL PARTNERS...
9.8%
ASTRAZENECA PLC
1.1%
Qube Research & Technologies Ltd
45%
RHUMBLINE ADVISERS
22%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sarborg Ltd |
13D/G
3/4/5
10%+ Owner
|
16%
|
$1,038,202
1,853,933 shares
|
$0 | 31 Mar 2025 |
| A.G.P. / ALLIANCE GLOBAL PARTNERS, LLC |
13D/G
|
9.8%
|
$620,659
1,108,320 shares
|
$0 | 31 Mar 2025 |
| ASTRAZENECA PLC |
13D/G
|
1.1%
|
$3,340
73,892 shares
|
$0 | 31 Mar 2025 |
| Qube Research & Technologies Ltd |
13F
Company
|
45%
|
$144,509
2,106,548 shares
|
— | 31 Dec 2024 |
| RHUMBLINE ADVISERS |
13F
Company
|
22%
|
$70,973
1,028,702 shares
|
— | 31 Dec 2024 |
| BARCLAYS PLC |
13F
Company
|
19%
|
$61,214
892,350 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
493,468
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
31
Q1 2025 holders
31
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|